Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Short acting beta-2 agonists for bronchiectasis.

F Franco1, A Sheikh, M Greenstone

  • 1Clinica di Malattie dell'Apparato Respiratorio, Universita' degli Studi di Modena e Reggio Emilia, Largo del Pozzo, 71, Modena, Italy.

The Cochrane Database of Systematic Reviews
|August 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Periodontitis Leads to Systemic Bone Loss through Neutrophil Reprogramming.

Journal of dental research·2025
Same author

Carbohydrate-Based Chiral Ligands for the Enantioselective Addition of Diethylzinc to Aldehydes.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

Artificial gravity protects bone and prevents bone marrow adipose tissue accumulation in humans during 60 d of bed rest.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025
Same author

Effectiveness of non-pharmaceutical interventions as implemented in the UK during the COVID-19 pandemic: a rapid review.

Journal of public health (Oxford, England)·2025
Same author

Allergic Rhinitis and its Impact on Asthma (ARIA) Classes in MASK-air Users.

Journal of investigational allergology & clinical immunology·2025
Same author

Comparing Interfractional Stability of Heart Dose Among Three Breath-Hold Radiotherapy Techniques in Breast Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

No randomized controlled trials (RCTs) were found for short-acting beta-2 agonists in bronchiectasis. Further RCTs are needed to evaluate this common treatment for airflow obstruction.

Area of Science:

  • Pulmonary Medicine
  • Respiratory Pharmacology

Background:

  • Bronchiectasis involves irreversible airway dilation, often treated with physiotherapy, antibiotics, and mucolytics.
  • Airflow obstruction and bronchial hyper-responsiveness are common in bronchiectasis, leading to frequent use of bronchodilator therapy.
  • Systematic evidence on the effectiveness of bronchodilator therapy in bronchiectasis is limited.

Purpose of the Study:

  • To review the effectiveness of short-acting beta-2 agonist therapy in managing airflow obstruction in bronchiectasis.
  • To identify and evaluate randomized controlled trials (RCTs) assessing short-acting beta-2 agonists for bronchiectasis.

Main Methods:

  • Systematic literature search of CENTRAL, MEDLINE, EMBASE, and CINAHL databases up to September 2002.
  • Inclusion criteria: randomized controlled trials (RCTs) of short-acting beta-2 agonists (inhaled or systemic) in bronchiectasis (excluding cystic fibrosis).

Related Experiment Videos

  • Exclusion criteria: non-RCTs, studies not relevant to the research question.

    • Main Results:

    • A total of 48 articles were identified; all were excluded after review.
    • No randomized controlled trials (RCTs) met the inclusion criteria for this review.
    • Data extraction and analysis were not possible due to the absence of relevant RCTs.

    Conclusions:

    • No RCTs were identified to investigate the role of short-acting beta-2 agonists in bronchiectasis.
    • Given the frequent use of this therapy, there is a clear need for RCTs to establish its effectiveness.
    • Further research is warranted to provide evidence-based guidance for bronchodilator use in bronchiectasis.